Want to see SE:S2M full AI Analyst Report?
Top Page
S2Medical AB Class B
(S2M)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/29/26
The score is primarily held back by volatile operating performance, with a return to sizable losses and negative free cash flow in TTM after a strong 2024. The low-debt balance sheet provides financial flexibility, but valuation support is limited due to negative earnings (negative P/E) and no dividend yield data. Technical analysis impact is neutral given missing indicator data.
Positive Factors
Long-term revenue growth
The substantial multi-year revenue increase indicates that S2Medical has expanded its commercial base and product adoption. Although recent growth has weakened, the larger revenue platform provides a foundation for recovery if execution and demand stabilize.
Negative Factors
Volatile revenue trajectory
The reversal from strong growth to declines reduces confidence in demand durability and forecasting reliability. Continued volatility could weaken operating leverage, make resource planning harder, and delay the ability to convert the expanded revenue base into consistent returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term revenue growth
The substantial multi-year revenue increase indicates that S2Medical has expanded its commercial base and product adoption. Although recent growth has weakened, the larger revenue platform provides a foundation for recovery if execution and demand stabilize.
Read all positive factors
S2Medical AB Class B (S2M) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr10.11M
Dividend YieldN/A
Average Volume (3M)4.15M
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,797,314,100
10 Day Avg. Volume3,690,541
30 Day Avg. Volume4,146,987
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.64
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr60.00M
S2Medical AB Class B Business Overview & Revenue Model
Company Description
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical...
S2Medical AB Class B Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.21M | 14.36M | 14.91M | 6.97M | 4.67M | 7.70M |
| Gross Profit | 14.49M | -2.07M | 14.14M | 5.04M | 5.17M | 7.10M |
| EBITDA | -1.36M | -1.41M | 6.82M | -13.53M | -26.37M | -18.73M |
| Net Income | -10.07M | -10.09M | 5.77M | -22.71M | -29.46M | -20.08M |
Balance Sheet | ||||||
| Total Assets | 16.90M | 16.90M | 18.09M | 21.41M | 25.29M | 29.68M |
| Cash, Cash Equivalents and Short-Term Investments | 564.00K | 907.00K | 1.00M | 1.52M | 3.72M | 9.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 207.69K |
| Total Liabilities | 6.84M | 7.03M | 6.29M | 19.75M | 18.22M | 15.00M |
| Stockholders Equity | 10.06M | 9.88M | 11.80M | 1.66M | 7.07M | 14.68M |
Cash Flow | ||||||
| Free Cash Flow | -444.79K | -1.35M | 2.49M | -17.67M | -30.03M | -22.76M |
| Operating Cash Flow | -444.79K | 675.00K | 3.12M | -16.52M | -28.13M | -19.67M |
| Investing Cash Flow | -1.53M | -2.02M | -634.00K | -1.15M | -1.76M | -3.02M |
| Financing Cash Flow | 1.25M | 1.25M | -5.54M | 15.47M | 24.14M | 6.85M |
S2Medical AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr19.67B | 32.36 | 10.82% | 0.95% | 0.82% | 77.45% | |
69 Neutral | kr2.05B | 28.26 | ― | 1.62% | 25.46% | 39.03% | |
67 Neutral | kr7.73B | 19.54 | 5.03% | 3.42% | -3.08% | -10.70% | |
54 Neutral | kr1.06B | -29.43 | -3.99% | ― | -0.34% | 29.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr564.21M | -67.29 | -2.84% | ― | -13.72% | 52.47% | |
46 Neutral | kr10.11M | -0.49 | -101.03% | ― | ― | ― |
* Healthcare Sector Average
SE:S2M
S2Medical AB Class B
0.01
>-0.01
-16.67%
SE:ALIF.B
AddLife AB
157.90
-22.33
-12.39%
SE:ARJO.B
Arjo AB
27.74
-5.05
-15.41%
SE:BACTI.B
Bactiguard Holding AB
16.15
-9.35
-36.67%
SE:SEDANA
Sedana Medical AB
10.52
-3.38
-24.32%
SE:STIL
Stille AB
228.50
-1.50
-0.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.